[HTML][HTML] Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

…, M Raponi, CA Karlovich, S Jaw-Tsai… - … England Journal of …, 2015 - Mass Medical Soc
Background Non–small-cell lung cancer (NSCLC) with a mutation in the gene encoding
epidermal growth factor receptor (EGFR) is sensitive to approved EGFR inhibitors, but …

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC

…, M Nacht, RC Petter, W Westlin, K Lin, S Jaw-Tsai… - Cancer discovery, 2013 - AACR
… In summary, CO-1686 is the first EGFR inhibitor in clinical development that is mutant-…
S. Jaw-Tsai has ownership interest (including patents) in Clovis Oncology, Inc. W. Pao has …

Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors

K Steece-Collier, LK Chambers, SS Jaw-Tsai… - Experimental …, 2000 - Elsevier
In the setting of nigrostriatal dopamine depletion, glutamatergic pathways to the striatum
and basal ganglia output nuclei become overactive. Systemically administered glutamate …

First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M).

…, BJ Solomon, V Papadimitrakopoulou, SS Jaw-Tsai… - 2014 - ascopubs.org
8010^ Background: Efficacy of existing EGFR tyrosine kinase inhibitors (TKIs) in NSCLC is
limited by emergence of the T790M mutation in approximately 60% of patients, and significant …

Fed-and fasted-state performance of pretomanid amorphous solid dispersions formulated with an enteric polymer

HT Nguyen, T Van Duong, S Jaw-Tsai… - Molecular …, 2023 - ACS Publications
Weakly acid polymers with pH-responsive solubility are being used with increasing frequency
in amorphous solid dispersion (ASD) formulations of drugs with low aqueous solubility. …

[HTML][HTML] A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours

…, P Roxburgh, H Giordano, S Jaw-Tsai, S Goble… - British journal of …, 2017 - nature.com
… Rucaparib (formerly known as AG-014699 and PF-01367338) is a potent small-molecule
inhibitor of PARP-1, PARP-2, and PARP-3 that is being developed for the treatment of ovarian …

Pharmacokinetic study of rucaparib in patients with advanced solid tumors

…, S Watkins, S Goble, S JawTsai… - Clinical …, 2019 - Wiley Online Library
The phase 1‐2 study CO‐338‐010 (Study 10; NCT01482715) is evaluating single‐agent
rucaparib, a poly(ADP‐ribose) polymerase inhibitor, administered orally to patients with an …

CP-101,606, an NR2B subunit selective NMDA receptor antagonist, inhibits NMDA and injury induced c-fos expression and cortical spreading depression in rodents

…, MJ Pagnozzi, P Butler, BL Chenard, SS Jaw-Tsai… - …, 2000 - Elsevier
(1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol (CP-101,606) is
a noncompetitive antagonist of N-methyl-D-aspartate (NMDA) receptors containing the …

Evaluation of in vitro absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) …

M Liao, S Jaw-Tsai, J Beltman, AD Simmons… - Xenobiotica, 2020 - Taylor & Francis
… guidance to recommend routine evaluation of a drug’s interactions with major cytochrome
P450 (CYP) enzymes … Jaw-Tsai was an employee of Clovis Oncology at the time of the study. …

[HTML][HTML] Combination therapy of varenicline with nicotine replacement therapy is better than varenicline alone: a systematic review and meta-analysis of randomized …

PH Chang, CH Chiang, WC Ho, PZ Wu, JS Tsai… - BMC public health, 2015 - Springer
… We used Begg’s rank correlation test and Egger’s regression test for statistical verification
of bias [13]. The test results were generated by Comprehensive Meta-Analysis Version 2 …